IDT Biologika GmbH and Oncotec Pharma Produktion have made several investments to increase their respective production capacities. IDT will invest €40 million in its vaccine and parenteral sterile fill-and-finish capacities in syringes, vials, lyophilization, and packaging at its BioPharmaPark in Dessau-Roβlau. Among the upgrades are new serialization and anti-counterfeiting capabilities designed to enable the authentication of finished pharmaceuticals. IDT also recently started up its new production capacity dedicated to sterile parenteral drug products, including vaccines and biologics. Capacity to manufacture vial-based products in liquid and lyophilized form will increase to 60 million units per year.
 
Oncotec Pharma, a manufacturer of aseptically produced cytostatic drug products, is investing €30 million to expand sterile parenteral oncology drug manufacturing capacity within IDT’s BioPharmaPark. The expansion projects are expected to be complete in 2016.
 
“Manufacturing biologics as well as sterile cytostatic oncology drugs with the highest standard of reliability and quality is among the most challenging tasks within the pharmaceutical industry,” said Dr. Ralf Pfirmann, chief executive officer of IDT Biologika. “These drugs are highly potent and require a very high level of care in manufacturing and storage. Both IDT and Oncotec have a proven track record of success in these classes of drugs, given our comprehensive experience in biologics (IDT) and cytostatic (Oncotec) medicines.”
 
“Our investment coupled with the enhanced manufacturing capabilities within BioPharmaPark will offer the marketplace access to the latest technologies and the highest GMP-quality production lines in the world,” said Dr. Jan-Arne Gewert, managing director, Oncotec Pharma Produktion. “These investments will further elevate BioPharmaPark as a high-tech complex with unique technological capabilities.”